Molecular Partners’ proprietary Radio DARPin Therapy (RDT) platform represents a unique and innovative delivery system designed to deliver radioactive payloads to solid tumors without accumulating in ...

Molecular Partners (NASDAQ:MOLN) hosted a webcast to discuss clinical imaging and dosimetry data for MP0712, its ...

Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...

Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing ...

Molecular Partners AG announced positive results from a Phase 1/2a trial of its tetraspecific T-cell engager MP0533 for relapsed/refractory acute myeloid leukemia (AML) during the 30th EHA Congress.

The MarketWatch News Department was not involved in the creation of this content. -- Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data ...

Molecular Partners and Orano Med expand collaboration to develop ten 212Pb-Radio-DARPin therapy candidates, initiating clinical trials in 2025. Molecular Partners AG and Orano Med have expanded their ...

Expanded data from the first three cohorts and data from fourth cohort will be presented at the ASH Annual Meeting and Exposition ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...